CAR T cell immunotherapy for human cancer
Top Cited Papers
- 23 March 2018
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 359 (6382) , 1361-1365
Abstract
Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.Keywords
Funding Information
- National Cancer Institute (RO1CA226983)
- National Cancer Institute (5R01CA165206)
- National Cancer Institute (1P01CA214278)
This publication has 66 references indexed in Scilit:
- The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityCancer Immunology, Immunotherapy, 2017
- Fully human CD19-specific chimeric antigen receptors for T-cell therapyLeukemia, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- The urgent need to recover MHC class I in cancers for effective immunotherapyCurrent Opinion in Immunology, 2016
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing CircuitsCell, 2016
- Engineering CAR-T cells: Design conceptsTrends in Immunology, 2015
- Perspective: Assembly line immunotherapyNature, 2013
- Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategiesEuropean Journal of Immunology, 2012
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regionsBiochemical and Biophysical Research Communications, 1987